Viruses | Selected Papers on Antiviral Strategies and Drug Resistance
1. “Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review”
by Carolyn Chu, Kaiming Tao, Vinie Kouamou, Ava Avalos, Jake Scott, Philip M. Grant, Soo-Yon Rhee, Suzanne M. McCluskey, Michael R. Jordan, Rebecca L. Morgan et al.
Viruses 2024, 16(3), 399; https://doi.org/10.3390/v16030399
Available online: https://www.mdpi.com/1999-4915/16/3/399
2. “Recent Advances on Targeting Proteases for Antiviral Development”
by Pedro Henrique Oliveira Borges, Sabrina Baptista Ferreira and Floriano Paes Silva
Viruses 2024, 16(3), 366; https://doi.org/10.3390/v16030366
Available online: https://www.mdpi.com/1999-4915/16/3/366
3. “Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat Resistance”
by Haydar Witwit, Beatrice Cubitt, Roaa Khafaji, Esteban M. Castro, Miguel Goicoechea, Maria M. Lorenzo, Rafael Blasco, Luis Martinez-Sobrido and Juan C. de la Torre
Viruses 2025, 17(1), 92; https://doi.org/10.3390/v17010092
Available online: https://www.mdpi.com/1999-4915/17/1/92
4. “Combinations of Bacteriophage Are Efficacious against Multidrug-Resistant Pseudomonas aeruginosa and Enhance Sensitivity to Carbapenem Antibiotics”
by Christopher J. Kovacs, Erika M. Rapp, William R. Rankin, Sophia M. McKenzie, Brianna K. Brasko, Katherine E. Hebert, Beth A. Bachert, Andrew R. Kick, F. John Burpo and Jason C. Barnhill
Viruses 2024, 16(7), 1000; https://doi.org/10.3390/v16071000
Available online: https://www.mdpi.com/1999-4915/16/7/1000
5. “Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019”
by Chie Yamamoto, Masashi Taniguchi, Keitaro Furukawa, Toru Inaba, Yui Niiyama, Daisuke Ide, Shinsuke Mizutani, Junya Kuroda, Yoko Tanino, Keisuke Nishioka et al.
Viruses 2024, 16(5), 718; https://doi.org/10.3390/v16050718
Available online: https://www.mdpi.com/1999-4915/16/5/718
6. “Trends in and Risk Factors for Drug Resistance in Mycobacterium tuberculosis in HIV-Infected Patients”
by Xiaoqin Le, Xueqin Qian, Li Liu, Jianjun Sun, Wei Song, Tangkai Qi, Zhenyan Wang, Yang Tang, Shuibao Xu, Junyang Yang et al.
Viruses 2024, 16(4), 627; https://doi.org/10.3390/v16040627
Available online: https://www.mdpi.com/1999-4915/16/4/627
7. “Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases”
by Susanne C. Duwe, Jeanette Milde, Alla Heider, Marianne Wedde, Brunhilde Schweiger and Ralf Dürrwald
Viruses 2024, 16(7), 1109; https://doi.org/10.3390/v16071109
Available online: https://www.mdpi.com/1999-4915/16/7/1109
8. “SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations”
by Vinicius Cardoso Soares, Isabela Batista Gonçalves Moreira and Suelen Silva Gomes Dias
Viruses 2025, 17(8), 1064; https://doi.org/10.3390/v17081064
Available online: https://www.mdpi.com/1999-4915/17/8/1064
9. “Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal”
by Victor Pimentel, Marta Pingarilho, Cruz S. Sebastião, Mafalda Miranda, Fátima Gonçalves, Joaquim Cabanas, Inês Costa, Isabel Diogo, Sandra Fernandes, Olga Costa et al.
Viruses 2024, 16(4), 622; https://doi.org/10.3390/v16040622
Available online: https://www.mdpi.com/1999-4915/16/4/622
10. “The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro”
by Xiaojia Guo, Lei Zhao, Wei Li, Ruiyuan Cao and Wu Zhong
Viruses 2024, 16(9), 1467; https://doi.org/10.3390/v16091467
Available online: https://www.mdpi.com/1999-4915/16/9/1467
